Search This Blog

Monday, September 24, 2018

Loxo Oncology initiated at Leerink


Loxo Oncology initiated with an Outperform at Leerink. Leerink analyst Andrew Berens started Loxo Oncology with an Outperform rating and $205 price target.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)